Q4 2025 OraSure Technologies Inc Earnings Call Transcript
Key Points
- OraSure Technologies Inc (OSUR) reported total revenue of $26.8 million for Q4 2025, exceeding the midpoint of their guidance range.
- The company is launching two new products in mid-2026: a rapid molecular self-test for chlamydia and gonorrhea (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections.
- OraSure Technologies Inc (OSUR) expanded its presence in Canada with the launch of the OraQuick HIV Self-Test, the first oral HIV self-test licensed by Health Canada.
- The integration of BioMedomics is progressing well, with strong demand for the Sickle SCAN test, particularly in Africa and Latin America.
- The company ended the year with zero debt and $199 million in cash and cash equivalents, reflecting a strong balance sheet.
- OraSure Technologies Inc (OSUR) reported a GAAP operating loss of $20.1 million and a non-GAAP operating loss of $15.2 million for Q4 2025.
- Operating cash flow was negative $9 million in the fourth quarter, attributed to investments in the Sherlock platform and clinical trials.
- The company anticipates lower R&D expenses in 2026, but ongoing clinical trials will continue to incur costs.
- There is uncertainty in the regulatory review process for the new product launches, which could impact the timing of revenue ramp-up.
- The company is operating at approximately 30% capacity, indicating underutilization of manufacturing resources.
Good day, and thank you for standing by. Welcome to the OraSure Technologies 2025 fourth-quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker for today, Jason Plagman, Vice President of Investor Relations. Please go ahead.
Good afternoon, and welcome to OraSure Technologies fourth-quarter 2025 earnings call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer; and Kenneth McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded, and the recording can be found on our Investor Relations website.
Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, performance,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
